32/120
1.3 / 5 stars
All 120 Win/Lose results shown below
PRPH Roast Me summary
ProPhase Labs, Inc. (PRPH). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LosePRPH / S&P 0.00% / 15.20% |
LosePRPH / S&P -31.16% / 15.00% |
LosePRPH / S&P PRPH unavailable / 50.40% |
| 2026-Q10/3 |
LosePRPH / S&P -80.00% / -4.33% |
LosePRPH / S&P -30.15% / 11.30% |
LosePRPH / S&P PRPH unavailable / 27.70% |
| 2025-Q40/3 |
LosePRPH / S&P -90.22% / 2.65% |
LosePRPH / S&P -35.82% / 9.00% |
LosePRPH / S&P PRPH unavailable / 13.40% |
| 2025-Q31/3 |
WinPRPH / S&P 17.95% / 8.12% |
LosePRPH / S&P PRPH unavailable / 4.61% |
LosePRPH / S&P PRPH unavailable / 13.45% |
| 2025-Q20/3 |
LosePRPH / S&P -2.50% / 10.94% |
LosePRPH / S&P -11.64% / 4.83% |
LosePRPH / S&P PRPH unavailable / 10.63% |
| 2025-Q10/3 |
LosePRPH / S&P -47.37% / -4.27% |
LosePRPH / S&P -67.59% / 4.98% |
LosePRPH / S&P PRPH unavailable / 10.57% |
| 2024-Q40/3 |
LosePRPH / S&P -68.60% / 2.41% |
LosePRPH / S&P -80.65% / 5.25% |
LosePRPH / S&P PRPH unavailable / 6.15% |
| 2024-Q30/3 |
LosePRPH / S&P -42.11% / 5.89% |
LosePRPH / S&P -101.00% / 5.89% |
LosePRPH / S&P PRPH unavailable / 6.11% |
| 2024-Q20/3 |
LosePRPH / S&P -35.39% / 4.28% |
LosePRPH / S&P -91.95% / 5.38% |
LosePRPH / S&P PRPH unavailable / 5.12% |
| 2024-Q11/3 |
WinPRPH / S&P 43.14% / 10.56% |
LosePRPH / S&P -80.90% / 5.71% |
LosePRPH / S&P -434.15% / 5.59% |
| 2023-Q40/3 |
LosePRPH / S&P 3.43% / 11.69% |
LosePRPH / S&P -71.48% / 6.81% |
LosePRPH / S&P -196.08% / 7.78% |
| 2023-Q30/3 |
LosePRPH / S&P -39.81% / -3.27% |
LosePRPH / S&P -57.04% / 7.52% |
LosePRPH / S&P -130.05% / -5.03% |
| 2023-Q20/3 |
LosePRPH / S&P -4.72% / 8.74% |
LosePRPH / S&P -40.16% / 9.50% |
LosePRPH / S&P -112.58% / -8.57% |
| 2023-Q10/3 |
LosePRPH / S&P -20.87% / 7.50% |
LosePRPH / S&P -15.17% / 10.77% |
LosePRPH / S&P -59.80% / -15.69% |
| 2022-Q42/3 |
LosePRPH / S&P -14.63% / 7.56% |
WinPRPH / S&P 55.17% / 11.88% |
WinPRPH / S&P 155.00% / -17.99% |
| 2022-Q31/3 |
LosePRPH / S&P -11.04% / -4.88% |
WinPRPH / S&P 273.85% / 13.47% |
LosePRPH / S&P PRPH unavailable / -1.41% |
| 2022-Q22/3 |
WinPRPH / S&P 87.79% / -16.10% |
WinPRPH / S&P 292.78% / 13.71% |
LosePRPH / S&P PRPH unavailable / 11.04% |
| 2022-Q12/3 |
WinPRPH / S&P 2.28% / -4.60% |
WinPRPH / S&P 298.97% / 15.97% |
LosePRPH / S&P PRPH unavailable / 42.23% |
| 2021-Q42/3 |
WinPRPH / S&P 37.88% / 11.03% |
WinPRPH / S&P 444.59% / 15.00% |
LosePRPH / S&P PRPH unavailable / 96.40% |
| 2021-Q31/3 |
LosePRPH / S&P -16.13% / 0.58% |
WinPRPH / S&P 212.58% / 10.77% |
LosePRPH / S&P PRPH unavailable / 69.42% |
| 2021-Q21/3 |
LosePRPH / S&P -12.08% / 8.55% |
WinPRPH / S&P 192.66% / 6.58% |
LosePRPH / S&P PRPH unavailable / 51.81% |
| 2021-Q11/3 |
LosePRPH / S&P -19.39% / 6.17% |
WinPRPH / S&P 195.33% / -1.06% |
LosePRPH / S&P PRPH unavailable / 7.39% |
| 2020-Q42/3 |
WinPRPH / S&P 165.32% / 12.15% |
WinPRPH / S&P 46.96% / -3.72% |
LosePRPH / S&P PRPH unavailable / -33.42% |
| 2020-Q32/3 |
WinPRPH / S&P 140.28% / 8.93% |
WinPRPH / S&P 15.37% / -2.04% |
LosePRPH / S&P PRPH unavailable / -27.10% |
| 2020-Q21/3 |
LosePRPH / S&P -23.81% / 20.54% |
WinPRPH / S&P 8.73% / -0.46% |
LosePRPH / S&P PRPH unavailable / -27.11% |
| 2020-Q11/3 |
WinPRPH / S&P -4.06% / -19.60% |
LosePRPH / S&P -21.52% / 3.47% |
LosePRPH / S&P PRPH unavailable / -14.75% |
| 2019-Q41/3 |
WinPRPH / S&P 15.16% / 9.07% |
LosePRPH / S&P -24.76% / 5.36% |
LosePRPH / S&P PRPH unavailable / 2.99% |
| 2019-Q30/3 |
LosePRPH / S&P -10.23% / 1.70% |
LosePRPH / S&P -17.86% / 5.02% |
LosePRPH / S&P -411.11% / 0.21% |
| 2019-Q20/3 |
LosePRPH / S&P -28.57% / 4.30% |
LosePRPH / S&P -23.82% / 6.64% |
LosePRPH / S&P -353.85% / 8.65% |
| 2019-Q10/3 |
LosePRPH / S&P 3.16% / 13.65% |
LosePRPH / S&P -3.74% / 8.12% |
LosePRPH / S&P -2500.00% / 14.29% |
| 2018-Q42/3 |
WinPRPH / S&P 5.00% / -13.52% |
WinPRPH / S&P 33.03% / 9.05% |
LosePRPH / S&P -105.79% / 18.23% |
| 2018-Q31/3 |
LosePRPH / S&P -7.69% / 7.71% |
WinPRPH / S&P 103.35% / 10.21% |
LosePRPH / S&P -95.98% / 19.06% |
| 2018-Q22/3 |
WinPRPH / S&P 48.87% / 3.43% |
WinPRPH / S&P 184.50% / 9.03% |
LosePRPH / S&P -94.35% / 14.46% |
| 2018-Q12/3 |
WinPRPH / S&P 36.41% / -0.76% |
WinPRPH / S&P 215.65% / 7.68% |
LosePRPH / S&P -99.58% / 12.46% |
| 2017-Q41/3 |
LosePRPH / S&P 1.40% / 6.64% |
WinPRPH / S&P 134.59% / 7.03% |
LosePRPH / S&P PRPH unavailable / 13.82% |
| 2017-Q30/3 |
LosePRPH / S&P 2.39% / 4.48% |
LosePRPH / S&P PRPH unavailable / 5.68% |
LosePRPH / S&P PRPH unavailable / 17.57% |
| 2017-Q20/3 |
LosePRPH / S&P -7.93% / 3.09% |
LosePRPH / S&P PRPH unavailable / 4.83% |
LosePRPH / S&P PRPH unavailable / 17.74% |
| 2017-Q11/3 |
WinPRPH / S&P 13.50% / 6.07% |
LosePRPH / S&P PRPH unavailable / 3.67% |
LosePRPH / S&P PRPH unavailable / 13.32% |
| 2016-Q41/3 |
LosePRPH / S&P 1.52% / 3.82% |
WinPRPH / S&P 67.04% / 2.09% |
LosePRPH / S&P PRPH unavailable / 7.05% |
| 2016-Q31/3 |
WinPRPH / S&P 50.38% / 3.85% |
LosePRPH / S&P -130.28% / 0.20% |
LosePRPH / S&P PRPH unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | PRPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.41% | 20.78% |
| Annualized return | -99.41% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | PRPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.96% | 83.14% |
| Annualized return | -78.99% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | PRPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.80% | 319.30% |
| Annualized return | -46.28% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |